RGPX (Regenerex Pharma) Short-Term Debt: $3.55 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenerex Pharma Short-Term Debt?

Regenerex Pharma RGPX Short-Term Debt is $3.55 Mil as of Sep. 2025.

Regenerex Pharma's Short-Term Debt for the quarter that ended in Sep. 2025 was $3.55 Mil.

Regenerex Pharma's quarterly Short-Term Debt increased from Mar. 2025 ($3.60 Mil) to Jun. 2025 ($3.63 Mil) but then declined from Jun. 2025 ($3.63 Mil) to Sep. 2025 ($3.55 Mil).

Regenerex Pharma's annual Short-Term Debt increased from Mar. 2023 ($0.22 Mil) to Mar. 2024 ($2.99 Mil) and increased from Mar. 2024 ($2.99 Mil) to Mar. 2025 ($3.60 Mil).

Regenerex Pharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Regenerex Pharma Short-Term Debt Related Terms

Regenerex Pharma Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Regenerex Pharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerex Pharma Short-Term Debt Chart

Regenerex Pharma Annual Data
Trend Nov14 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.15 0.22 2.99 3.60

Regenerex Pharma Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.69 3.84 3.60 3.63 3.55
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $3.55 Mil mean?
Regenerex Pharma (RGPX) has a Short-Term Debt of $3.55 Mil as of Sep. 2025.
Is Regenerex Pharma's Short-Term Debt too high?
Regenerex Pharma's current Short-Term Debt is $3.55 Mil.
How does Regenerex Pharma's Short-Term Debt compare to CABN and TEKXD?
Regenerex Pharma's Short-Term Debt of $3.55 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Regenerex Pharma's current Short-Term Debt is $3.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerex Pharma stock overvalued right now?
Regenerex Pharma (RGPX) has a current Short-Term Debt of $3.55 Mil. The current Short-Term Debt is $3.55 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Regenerex Pharma (RGPX), the current Short-Term Debt is $3.55 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerex Pharma Business Description

Address 5348 Vegas Drive, Suite 177, Las Vegas, NV, USA, 89108
Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.